Axsome Therapeutics Inc

Axsome Therapeutics is a biopharmaceutical company focused on developing and commercializing treatments for central nervous system (CNS) disorders spanning both psychiatry and neurology. The company markets three FDA-approved products: AUVELITY, a first-in-class oral NMDA receptor antagonist and sigma-1 receptor agonist approved for major depressive disorder in adults and for agitation associated with dementia due to Alzheimer's disease; SUNOSI, the first and only dopamine-norepinephrine reuptake inhibitor (DNRI) approved for excessive daytime sleepiness associated with obstructive sleep apnea or narcolepsy; and SYMBRAVO, an oral multi-mechanistic COX-2 preferential inhibitor and 5-HT1B/1D agonist for the acute treatment of migraine in adults. Axsome maintains a deep development pipeline of six novel product candidates targeting 10 indications including ADHD, binge eating disorder, smoking cessation, schizophrenia, narcolepsy, fibromyalgia, shift work disorder, epilepsy, MDD with excessive daytime sleepiness symptoms, and Tourette syndrome. The company's portfolio leverages novel mechanisms of action including NMDA antagonism, selective norepinephrine reuptake inhibition, TAAR1 agonism, PDE10A inhibition, and GABAA receptor modulation. Axsome estimates its total portfolio represents over $18 billion in annual peak sales potential across marketed and pipeline products. Updated Aug 10, 2026